Early trial tests virus + drug combo for tough bladder cancers

NCT ID NCT04610671

Summary

This small, early-stage study tested the safety of a two-part treatment for muscle-invasive bladder cancer in patients who could not receive standard chemotherapy. The treatment combined a modified cold virus (CG0070) placed directly into the bladder with an immunotherapy drug (nivolumab) given by IV. The main goal was to see if this combination was safe and to gather initial information on how well it might work before surgery to remove the bladder.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

Conditions

Explore the condition pages connected to this study.